80 FR 11682 - Center for Scientific Review; Amended Notice of Meeting
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health Federal Register Volume 80, Issue 42 (March 4, 2015)
National Institutes of Health
Federal Register Volume 80, Issue 42 (March 4, 2015)
| Page Range | 11682-11682 | |
| FR Document | 2015-04408 |
[Federal Register Volume 80, Number 42 (Wednesday, March 4, 2015)] [Notices] [Page 11682] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2015-04408] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Amended Notice of Meeting Notice is hereby given of a change in the meeting of the Center for Scientific Review Special Emphasis Panel, March 05, 2015, 11:00 a.m. to March 05, 2015, 05:00 p.m., National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD, 20892 which was published in the Federal Register on February 24, 2015, 80 FR 9738. The meeting will be held on March 12, 2015. The meeting location and time remain the same. The meeting is closed to the public. Dated: February 25, 2015. David Clary, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2015-04408 Filed 3-3-15; 8:45 am] BILLING CODE 4140-01-P
![11682 Federal Register / Vol. 80, No. 42 / Wednesday, March 4, 2015 / Notices
to learn about possible modifications the number of registrants requesting to DEPARTMENT OF HEALTH AND
before coming to the meeting. speak is greater than can be reasonably HUMAN SERVICES
Agenda: On March 24, 2015, the accommodated during the scheduled
Pediatric Advisory Committee (PAC) open public hearing session, FDA may National Institutes of Health
will meet to discuss pediatric-focused conduct a lottery to determine the
safety reviews, as mandated by the Best speakers for the scheduled open public National Institute of Neurological
Pharmaceuticals for Children Act (Pub. hearing session. The contact person will Disorders and Stroke; Notice of
L. 107–109) and the Pediatric Research notify interested persons regarding their Meeting
Equity Act (Pub. L. 108–155). The PAC request to speak by March 9, 2015. Pursuant to section 10(d) of the
will meet to discuss the following Persons attending FDA’s advisory Federal Advisory Committee Act, as
products: CYMBALTA (duloxetine committee meetings are advised that the amended (5 U.S.C. App.), notice is
hydrochloride), QUILLIVANT XR Agency is not responsible for providing hereby given of a meeting of the
(methylphenidate hydrochloride), access to electrical outlets. National Advisory Neurological
LUNESTA (eszopiclone), RISPERDAL FDA welcomes the attendance of the Disorders and Stroke Council.
(risperidone), OXTELLAR XR public at its advisory committee The meeting will be open to the
(oxcarbazepine), REVATIO (sildenafil), meetings and will make every effort to public as indicated below, with
ADVAIR HFA (fluticasone propionate/ accommodate persons with physical attendance limited to space available.
salmeterol), DYMISTA (azelastine disabilities or special needs. If you Individuals who plan to attend and
hydrochloride/fluticasone proprionate), require special accommodations due to need special assistance, such as sign
QNASL (beclomethasone dipropionate), a disability, please contact Walter language interpretation or other
VENOFER (iron sucrose), INVIRASE Ellenberg at least 7 days in advance of reasonable accommodations, should
(saquinavir), ALTABAX Ointment the meeting. notify the Contact Person listed below
(retapamulin), FluMist FDA is committed to the orderly in advance of the meeting.
QUADRIVALENT (influenza vaccine conduct of its advisory committee The meeting will be closed to the
live, intranasal), FLUARIX meetings. Please visit our Web site at public in accordance with the
QUADRIVALENT (influenza virus http://www.fda.gov/Advisory provisions set forth in sections
vaccine), Medtronic ACTIVA Committees/AboutAdvisoryCommittees/ 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
DYSTONIA THERAPY, and ucm111462.htm for procedures on as amended. The grant applications and
LIPOSORBER LA–15 System. In public conduct during advisory the discussions could disclose
addition, there will be a short committee meetings. confidential trade secrets or commercial
presentation of the ethical issues Notice of this meeting is given under property such as patentable materials,
discussed by the Pediatric Ethics the Federal Advisory Committee Act (5 and personal information concerning
Subcommittee of the PAC on March 23, U.S.C. app. 2). individuals associated with the grant
2015. applications, the disclosure of which
FDA intends to make background Dated: February 26, 2015.
Jill Hartzler Warner, would constitute a clearly unwarranted
material available to the public no later
invasion of personal privacy.
than 2 business days before the meeting. Associate Commissioner for Special Medical
If FDA is unable to post the background Programs. Name of Committee: National Advisory
material on its Web site prior to the [FR Doc. 2015–04394 Filed 3–3–15; 8:45 am] Neurological Disorders and Stroke Council.
Date: May 28–29, 2015.
meeting, the background material will BILLING CODE 4164–01–P
Open: May 28, 2015, 8:00 a.m. to 3:00 p.m.
be made publicly available at the Agenda: Report by the Director, NINDS;
location of the advisory committee Report by the Associate Director for
meeting, and the background material DEPARTMENT OF HEALTH AND Extramural Research; Administrative and
will be posted on FDA’s Web site after HUMAN SERVICES Program Developments; and an Overview of
the meeting. Background material is the NINDS Intramural Program.
available at http://www.fda.gov/ National Institutes of Health Place: National Institutes of Health,
AdvisoryCommittees/Calendar/ Building 31, 31 Center Drive, Conference
default.htm. Scroll down to the Center for Scientific Review; Amended Room 10, Bethesda, MD 20892.
Notice of Meeting Closed: May 28, 2015, 3:00 p.m. to 4:45
appropriate advisory committee link. p.m.
Procedure: Interested persons may Notice is hereby given of a change in Agenda: To review and evaluate grant
present data, information, or views, the meeting of the Center for Scientific applications.
orally or in writing, on issues pending Review Special Emphasis Panel, March Place: National Institutes of Health,
before the committee. Written 05, 2015, 11:00 a.m. to March 05, 2015, Building 31, 31 Center Drive, Conference
submissions may be made to the contact Room 10, Bethesda, MD 20892.
05:00 p.m., National Institutes of Health, Closed: May 28, 2015, 4:45 p.m. to 5:15
person on or before March 16, 2015. 6701 Rockledge Drive, Bethesda, MD,
Oral presentations from the public will p.m.
20892 which was published in the Agenda: To review and evaluate the
be scheduled on March 24, 2015, Federal Register on February 24, 2015, Division of Intramural Research Board of
between approximately 9 a.m. and 10 80 FR 9738. Scientific Counselors’ Reports.
a.m. Those individuals interested in The meeting will be held on March Place: National Institutes of Health,
making formal oral presentations should 12, 2015. The meeting location and time Building 31, 31 Center Drive, Conference
notify the contact person and submit a remain the same. The meeting is closed Room 10, Bethesda, MD 20892.
mstockstill on DSK4VPTVN1PROD with NOTICES
brief statement of the general nature of Closed: May 29, 2015, 8:00 a.m. to 11:00
to the public. a.m.
the evidence or arguments they wish to
present, the names and addresses of Dated: February 25, 2015. Agenda: To review and evaluate grant
David Clary, applications.
proposed participants, and an Place: National Institutes of Health,
indication of the approximate time Program Analyst, Office of Federal Advisory
Building 31, 31 Center Drive, Conference
requested to make their presentation on Committee Policy.
Room 10, Bethesda, MD 20892.
or before March 6, 2015. Time allotted [FR Doc. 2015–04408 Filed 3–3–15; 8:45 am] Contact Person: Robert Finkelstein, Ph.D.,
for each presentation may be limited. If BILLING CODE 4140–01–P Associate Director for Extramural Research,
VerDate Sep<11>2014 18:11 Mar 03, 2015 Jkt 235001 PO 00000 Frm 00054 Fmt 4703 Sfmt 4703 E:\FR\FM\04MRN1.SGM 04MRN1](https://thefederalregister.org/doc/80_FR_11724/page/1.svg)
Document Created: 2018-02-21 09:31:41
Document Modified: 2018-02-21 09:31:41
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| FR Citation | 80 FR 11682 |
2024 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR